Investigation of satisfaction and efficacy after switching from daily DPP-4 inhibitors to weekly trelagliptin in patients with type 2 diabetes -prospective observational study-
Phase of Trial: Phase IV
Latest Information Update: 01 Dec 2017
At a glance
- Drugs Trelagliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Takeda
- 01 Dec 2017 Study protocol published in the Diabetes Therapy
- 30 Oct 2017 Status changed from active, no longer recruiting to completed.
- 31 Jul 2017 Planned number of patients changed from 240 to 211.